Consensus Zai Lab Limited

Stocks

ZLAB

US98887Q1040

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2026-08-26 pm EDT			Pre-market 08:00:03 am
26.03 ^USD	-0.53%		26.86	+3.21%

Aug. 25	Zai Lab's Net Loss Widens 14% in H1, Revenue Drops 6%	MT
Aug. 25	Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT

Evolution of the Average Target: Zai Lab Limited

Evolution of the Target Price: Zai Lab Limited

Changes in Analyst Recommendations: Zai Lab Limited

365bcffdfd7879e375fee.lBbbSoYPFHCSt07bj7Qxp2N6V4ALkBOUn2Pu11svlLc._F6cJPJ9X0XdwXf2yIZ2lwFLCM1x9Fe5-je2oz95-v37Lpkm4nxuIP76Fw~b65328052196a656ea05c830c65a98ce

Analysts' recommendations: Zai Lab Limited

Jan. 07	UBS Initiates Zai Lab at Buy With $35 Price Target	MT
Nov. 04	Zai Lab updates on Amgen's bemarituzumab Phase 1B/3 Fortitude-102 study	RE
Nov. 04	Zai Lab Limited Announces Update on Amgen's Bemarituzumab Phase 1B/3 Fortuda-102 Study	CI
25-03-13	JPMorgan Adjusts Price Target on Zai Lab to $51 From $44, Keeps Overweight Rating	MT
25-03-03	BofA Securities Downgrades Zai Lab to Neutral	MT
24-07-12	JPMorgan Cuts Price Target on Zai Lab to $38 From $43, Maintains Overweight Rating	MT
23-12-14	Morgan Stanley Starts Coverage on Zai Lab with Overweight Rating, $47.50 Price Target	MT
23-10-26	Citigroup Adjusts Price Target on Zai Lab to $128 From $130, Maintains Buy Rating	MT
23-10-26	Goldman Sachs Lowers Price Target on Zai Lab to $73.34 From $82.47, Maintains Buy Rating	MT
23-08-10	Cantor Fitzgerald Initiates Coverage on Zai Lab With Overweight Rating, $70 Price Target	MT
23-06-12	BofA Adjusts Price Target on Zai Lab to $62.50 From $75, Maintains Buy Rating	MT
23-05-11	Citigroup Adjusts Price Target on Zai Lab to $130 From $138, Keeps Buy Rating	MT
23-03-16	JPMorgan Adjusts Price Target on Zai Lab to $70 From $79, Maintains Overweight Rating	MT
22-11-18	JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rating	MT
22-11-11	Citigroup Adjusts Price Target on Zai Lab to $127 From $199, Maintains Buy Rating	MT
22-08-09	Citigroup Adjusts Zai Lab's Price Target to $199 From $193, Reiterates Buy Rating	MT
22-05-25	CSPC Pharma Shares Fall After Weaker 1Q Profit	DJ
22-05-12	Citigroup Adjusts Zai Lab Price Target to $193 From $198, Maintains Buy Rating	MT
22-05-11	SVB Securities Adjusts Zai Lab Price Target to $95 From $101, Maintains Outperform Rating	MT
22-05-06	Guggenheim Adjusts Price Target for Zai Lab to $85 From $134, Maintains Buy Rating	MT
22-04-21	SVB Leerink Adjusts Zai Lab Price Target to $101 From $102, Maintains Outperform Rating	MT
22-04-04	JPMorgan Lowers Zai Lab's Price Target to $112 From $136, Maintains Overweight Rating	MT
22-03-03	Analyst recommendations: Acushnet, Bristol-Myers Squibb, Intel, iQIYI, Polymetal...
22-03-02	SVB Leerink Adjusts Zai Lab Price Target to $102 From $194, Maintains Outperform Rating	MT
21-12-03	Citigroup Raises Price Target for Zai Lab to $231 From $217, Maintains Buy Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ZAI LAB LIMITED					+27.31%
	REGENERON PHARMACEUTICALS, INC.					+3.15%
	MODERNA, INC.					-30.16%
	CSL LIMITED					-5.41%
	SAMSUNG BIOLOGICS CO.,LTD.					+23.09%
	UCB					+29.08%
	BIOGEN INC.					+6.85%
	INCYTE CORPORATION					-0.78%
	INNOVENT BIOLOGICS, INC.					+15.15%
	SWEDISH ORPHAN BIOVITRUM AB					+7.19%
	Average					+7.55%
	Weighted average by Cap.					+3.86%